PharmaNutrition最新文献_第2页

Polar Lipids: Pharma-nutritional potential in modern healthcare

IF 2.4 Q3 NUTRITION & DIETETICS

PharmaNutrition

Pub Date : 2024-12-01 DOI: 10.1016/j.phanu.2024.100413

Francesco Visioli

引用次数: 0

A comprehensive review of probiotic claims regulations: Updates from Asia-Pacific, United States, and Europe

IF 2.4 Q3 NUTRITION & DIETETICS

PharmaNutrition

Pub Date : 2024-12-01 DOI: 10.1016/j.phanu.2024.100423

Vandana Garg , Deepapriya Velumani , Yu-Chieh Lin , Abdul Haye

Background

Probiotics are defined, classified, and regulated differently across countries, which affects consumer protection and market access for manufacturers. This review examined the regulatory similarities and differences for probiotics in the APAC region, the U.S., and Europe to address these challenges.

Method

A detailed literature search was conducted on databases such as Google Scholar, PubMed, and open sources of relevant regulatory authorities. Relevant articles, guidelines, and recommendations related to probiotics in APAC, U.S. and Europe were screened and reviewed.

Results

Probiotics are categorized as "food" in U.S., Europe, Japan, Thailand, Malaysia, Singapore, and Indonesia, with Malaysia, Singapore, and Indonesia also classifying them as "health supplements." Other terms like “functional food," "novel food," and "health functional food" are used in various countries. Claims for probiotics also vary internationally. Countries such as China, Philippines, and Singapore have pre-approved claims, while the U.S., South Korea, Australia & New Zealand, and India do not have any pre-approved claim. Europe enforces the strictest rules and generally does not approve any probiotic health claims, whereas U.S. and APAC regions are more flexible. For instance, in Thailand, claim of “reducing disease risk” is permitted.

Conclusion

Harmonizing the regulations could benefit consumers and manufacturers by ensuring consistent standards and facilitating market entry. This would help industry stakeholders navigate the complex regulatory landscape and aid consumers in understanding the benefits of probiotic products.

{"title":"A comprehensive review of probiotic claims regulations: Updates from Asia-Pacific, United States, and Europe","authors":"Vandana Garg , Deepapriya Velumani , Yu-Chieh Lin , Abdul Haye","doi":"10.1016/j.phanu.2024.100423","DOIUrl":"10.1016/j.phanu.2024.100423","url":null,"abstract":"<div><h3>Background</h3><div>Probiotics are defined, classified, and regulated differently across countries, which affects consumer protection and market access for manufacturers. This review examined the regulatory similarities and differences for probiotics in the APAC region, the U.S., and Europe to address these challenges.</div></div><div><h3>Method</h3><div>A detailed literature search was conducted on databases such as Google Scholar, PubMed, and open sources of relevant regulatory authorities. Relevant articles, guidelines, and recommendations related to probiotics in APAC, U.S. and Europe were screened and reviewed.</div></div><div><h3>Results</h3><div>Probiotics are categorized as \"food\" in U.S., Europe, Japan, Thailand, Malaysia, Singapore, and Indonesia, with Malaysia, Singapore, and Indonesia also classifying them as \"health supplements.\" Other terms like “functional food,\" \"novel food,\" and \"health functional food\" are used in various countries. Claims for probiotics also vary internationally. Countries such as China, Philippines, and Singapore have pre-approved claims, while the U.S., South Korea, Australia & New Zealand, and India do not have any pre-approved claim. Europe enforces the strictest rules and generally does not approve any probiotic health claims, whereas U.S. and APAC regions are more flexible. For instance, in Thailand, claim of “reducing disease risk” is permitted.</div></div><div><h3>Conclusion</h3><div>Harmonizing the regulations could benefit consumers and manufacturers by ensuring consistent standards and facilitating market entry. This would help industry stakeholders navigate the complex regulatory landscape and aid consumers in understanding the benefits of probiotic products.</div></div>","PeriodicalId":20049,"journal":{"name":"PharmaNutrition","volume":"30 ","pages":"Article 100423"},"PeriodicalIF":2.4,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143148845","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The gut brain axis, effect of dietary changes and probiotics supplement on depression symptoms

IF 2.4 Q3 NUTRITION & DIETETICS

PharmaNutrition

Pub Date : 2024-12-01 DOI: 10.1016/j.phanu.2024.100424

Salma Hosny Abd-allah Mohamed, Ghada Mahmoud Khafagy, Inas El Sayed, Hala Ahmed Hussein

Introduction

Depression is a prevalent mental condition that adversely affects the lives of millions globally. Research has examined the correlation between alterations in gut microbiota composition and depression, leading to increasing interest in the possible use of probiotics to restore gut microbiota balance and enhance mental health outcomes.

Aim

Our aim is to examine the impact of probiotic supplementation on depression in healthy people. By assessing the impact of non-pharmacological therapies aimed at the gut-brain axis, we aspire to contribute to the advancement of accessible and efficacious treatments for depression.

Methods

We assessed socioeconomic status and depression score at baseline in a randomized controlled experiment of healthy people. We then randomly allocated individuals to the intervention group, which got probiotic supplements and health information regarding probiotic-rich diets, or the control group, which received their regular diet. At the end of 12 weeks, we repeated the same measurements.

Results

The study indicated a notable enhancement in depression levels within the intervention group. The median depression score declined from 8 (IQR: 6–9) prior to the intervention to 3 (IQR: 3–5) following the intervention, indicating a 62.5 % enhancement. The control group had a marginal deterioration in depression ratings within the same timeframe, with the median score rising from 8 (IQR: 6–9) to 8.5 (IQR: 7–10), indicating a 6.25 % drop.

Conclusions

Probiotics exert a beneficial influence on both the occurrence and intensity of depression symptoms in healthy people, greatly alleviating these symptoms.

{"title":"The gut brain axis, effect of dietary changes and probiotics supplement on depression symptoms","authors":"Salma Hosny Abd-allah Mohamed, Ghada Mahmoud Khafagy, Inas El Sayed, Hala Ahmed Hussein","doi":"10.1016/j.phanu.2024.100424","DOIUrl":"10.1016/j.phanu.2024.100424","url":null,"abstract":"<div><h3>Introduction</h3><div>Depression is a prevalent mental condition that adversely affects the lives of millions globally. Research has examined the correlation between alterations in gut microbiota composition and depression, leading to increasing interest in the possible use of probiotics to restore gut microbiota balance and enhance mental health outcomes.</div></div><div><h3>Aim</h3><div>Our aim is to examine the impact of probiotic supplementation on depression in healthy people. By assessing the impact of non-pharmacological therapies aimed at the gut-brain axis, we aspire to contribute to the advancement of accessible and efficacious treatments for depression.</div></div><div><h3>Methods</h3><div>We assessed socioeconomic status and depression score at baseline in a randomized controlled experiment of healthy people. We then randomly allocated individuals to the intervention group, which got probiotic supplements and health information regarding probiotic-rich diets, or the control group, which received their regular diet. At the end of 12 weeks, we repeated the same measurements.</div></div><div><h3>Results</h3><div>The study indicated a notable enhancement in depression levels within the intervention group. The median depression score declined from 8 (IQR: 6–9) prior to the intervention to 3 (IQR: 3–5) following the intervention, indicating a 62.5 % enhancement. The control group had a marginal deterioration in depression ratings within the same timeframe, with the median score rising from 8 (IQR: 6–9) to 8.5 (IQR: 7–10), indicating a 6.25 % drop.</div></div><div><h3>Conclusions</h3><div>Probiotics exert a beneficial influence on both the occurrence and intensity of depression symptoms in healthy people, greatly alleviating these symptoms.</div></div>","PeriodicalId":20049,"journal":{"name":"PharmaNutrition","volume":"30 ","pages":"Article 100424"},"PeriodicalIF":2.4,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143148846","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A therapeutic approach to identify leading molecules from natural products and therapeutic targets in CKD by network pharmacology 通过网络药理学从天然产品中发现主导分子并确定慢性肾脏病治疗靶点的治疗方法

IF 2.4 Q3 NUTRITION & DIETETICS

PharmaNutrition

Pub Date : 2024-11-21 DOI: 10.1016/j.phanu.2024.100421

Yugant Krishnakumar Talati, Anil Bhanudas Gaikwad

Chronic kidney disease (CKD), a condition characterized by diminished kidney function, affects approximately 10 % of the population worldwide. With its high mortality rate of ∼1.2 million, CKD poses a high global burden. The complexity increases severalfold due to its vast variety of aetiologies and relatively limited treatment options that, too, are associated with adverse effects. The continuous deterioration of the kidneys makes them reliant on external purification systems i.e., dialysis or whole kidney transplantation, both having certain limitations, making CKD one of the highly prevalent diseases across the globe. The multi-faceted disease requires multi-targeted therapies that can potentially improve CKD care. Natural products have long been considered the “holy grail” for many diseases, including CKD; their multi-targeting nature, fewer side effects, and ability to target multiple pathways have caught attention. The complexity increases when a single phytopharmaceutical cures a disease by acting on various targets and affecting diverse mechanisms. Identifying therapeutic targets and lead molecules thus becomes difficult and, at times, a big task! The network pharmacology (NP) tool has shifted this drug discovery paradigm towards a “multi-drug, multi-target” approach to underscore responsible molecular interconnections that unwind the therapeutic potential of natural products against CKD by predicting potential therapeutic targets and underlined molecular mechanisms. Applying NP for natural products in CKD can be a time-saving and cost-effective strategy. The present review emphasizes prominent classes of natural products and lead molecules obtained from herbal preparations, their explored multi-targeted effects against CKD, and novel targets predicted and validated using the NP approach.

慢性肾脏病（CKD）是一种以肾功能减退为特征的疾病，影响着全球约 10% 的人口。慢性肾脏病的死亡率高达 120 万，给全球造成了沉重的负担。由于病因种类繁多，治疗方法相对有限，而且还伴有不良反应，其复杂性增加了数倍。肾脏的持续恶化使其不得不依赖外部净化系统，即透析或全肾移植，这两种方法都有一定的局限性，从而使 CKD 成为全球高发疾病之一。这种多发性疾病需要多靶点疗法来改善 CKD 护理。长期以来，天然产品一直被认为是包括 CKD 在内的许多疾病的 "圣杯"；它们的多靶点性、较少的副作用以及靶向多种途径的能力引起了人们的关注。当一种植物药通过作用于不同靶点和影响不同机制来治疗疾病时，其复杂性就会增加。因此，确定治疗靶点和先导分子变得十分困难，有时甚至是一项艰巨的任务！网络药理学（NP）工具将这种药物发现范式转变为 "多药物、多靶点 "方法，通过预测潜在的治疗靶点和强调分子机制，强调负责任的分子相互联系，从而发掘天然产品治疗慢性肾功能衰竭的潜力。在 CKD 中应用天然产物 NP 可以是一种省时且具有成本效益的策略。本综述强调了从中草药制剂中获得的天然产品和先导分子的主要类别、它们对 CKD 的多靶点作用，以及使用 NP 方法预测和验证的新靶点。

{"title":"A therapeutic approach to identify leading molecules from natural products and therapeutic targets in CKD by network pharmacology","authors":"Yugant Krishnakumar Talati, Anil Bhanudas Gaikwad","doi":"10.1016/j.phanu.2024.100421","DOIUrl":"10.1016/j.phanu.2024.100421","url":null,"abstract":"<div><div>Chronic kidney disease (CKD), a condition characterized by diminished kidney function, affects approximately 10 % of the population worldwide. With its high mortality rate of ∼1.2 million, CKD poses a high global burden. The complexity increases severalfold due to its vast variety of aetiologies and relatively limited treatment options that, too, are associated with adverse effects. The continuous deterioration of the kidneys makes them reliant on external purification systems <em>i.e.,</em> dialysis or whole kidney transplantation, both having certain limitations, making CKD one of the highly prevalent diseases across the globe. The multi-faceted disease requires multi-targeted therapies that can potentially improve CKD care. Natural products have long been considered the “holy grail” for many diseases, including CKD; their multi-targeting nature, fewer side effects, and ability to target multiple pathways have caught attention. The complexity increases when a single phytopharmaceutical cures a disease by acting on various targets and affecting diverse mechanisms. Identifying therapeutic targets and lead molecules thus becomes difficult and, at times, a big task! The network pharmacology (NP) tool has shifted this drug discovery paradigm towards a “multi-drug, multi-target” approach to underscore responsible molecular interconnections that unwind the therapeutic potential of natural products against CKD by predicting potential therapeutic targets and underlined molecular mechanisms. Applying NP for natural products in CKD can be a time-saving and cost-effective strategy. The present review emphasizes prominent classes of natural products and lead molecules obtained from herbal preparations, their explored multi-targeted effects against CKD, and novel targets predicted and validated using the NP approach.</div></div>","PeriodicalId":20049,"journal":{"name":"PharmaNutrition","volume":"30 ","pages":"Article 100421"},"PeriodicalIF":2.4,"publicationDate":"2024-11-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142723157","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Efficacy and safety of crocin supplementation in patients with central serous chorioretinopathy, a pilot randomized double blinded clinical trial 中心性浆液性脉络膜视网膜病变患者补充巴豆苷的有效性和安全性--一项随机双盲临床试验

IF 2.4 Q3 NUTRITION & DIETETICS

PharmaNutrition

Pub Date : 2024-11-20 DOI: 10.1016/j.phanu.2024.100422

Mohammadkarim Johari, Alireza Attar, Mojtaba Heydari

Background

Central Serous Chorioretinopathy (CSCR) is a vision-threatening condition characterized by serous retinal detachment. Crocin, a carotenoid compound found in saffron, has demonstrated antioxidant and anti-inflammatory properties in various retinal diseases, but its efficacy in CSCR remains understudied.

Methods

In this randomized controlled trial, 40 patients with CSCR were assigned to receive either crocin (n=20) or placebo (n=20) over an eight-weeks period. Visual acuity, anatomical outcomes measured by optical coherence tomography (OCT), and adverse events were assessed at baseline and at the end of the intervention period.

Results

There were no significant differences observed in age, weight, body mass index, or gender distribution between the two groups (p > 0.05 for all comparisons). The changes in mean ETDRS letter score were significantly more in crocin group compared to the placebo group (4.27±3.63 vs 0.57±7.23, respectively, p=0.024). In the crocin group, 20 %, 40 % and 80 % of patients showed an improvement of 10,5 and 1 ETDRS letters, compared to only 7 %, 21 % and 29 % in the placebo group (p=0.316, p=0.280, p=0.005, respectively). While the crocin group exhibited greater mean reductions in sub-retinal fluid height, central macular thickness, and choroidal thickness compared to the placebo group, these differences did not reach statistical significance (p > 0.05 for all comparisons). No adverse events associated with the trial intervention were reported by any patient in either the crocin or placebo group.

Conclusion

The findings of this pilot study suggest that crocin supplementation may lead to improvements in visual acuity in patients with CSCR. Differences in anatomical outcomes between crocin and placebo groups did not reach statistical significance in this pilot study.

背景中心性浆液性脉络膜视网膜病变（CSCR）是一种以浆液性视网膜脱离为特征的威胁视力的疾病。藏红花中的类胡萝卜素化合物藏红花苷已在多种视网膜疾病中显示出抗氧化和抗炎特性，但其对 CSCR 的疗效仍未得到充分研究。在基线和干预期结束时，对视力、光学相干断层扫描（OCT）测量的解剖学结果和不良事件进行了评估。结果观察到两组患者在年龄、体重、体重指数或性别分布方面无显著差异（所有比较均为 0.05）。与安慰剂组相比，羊角霉素组平均 ETDRS 字母评分的变化明显更大（分别为 4.27±3.63 vs 0.57±7.23，P=0.024）。在巴豆苷组中，20%、40% 和 80% 的患者的 ETDRS 分值分别提高了 10、5 和 1 个字母，而安慰剂组仅有 7%、21% 和 29% 的患者的 ETDRS 分值分别提高了 10、5 和 1 个字母（P=0.316、P=0.280、P=0.005）。与安慰剂组相比，曲安奈德组视网膜下积液高度、黄斑中心厚度和脉络膜厚度的平均降低幅度更大，但这些差异未达到统计学意义（所有比较的 p 均为 0.05）。结论这项试验性研究的结果表明，补充巴豆苷可改善 CSCR 患者的视力。在这项试点研究中，巴豆苷组和安慰剂组在解剖结果上的差异未达到统计学意义。

{"title":"Efficacy and safety of crocin supplementation in patients with central serous chorioretinopathy, a pilot randomized double blinded clinical trial","authors":"Mohammadkarim Johari, Alireza Attar, Mojtaba Heydari","doi":"10.1016/j.phanu.2024.100422","DOIUrl":"10.1016/j.phanu.2024.100422","url":null,"abstract":"<div><h3>Background</h3><div>Central Serous Chorioretinopathy (CSCR) is a vision-threatening condition characterized by serous retinal detachment. Crocin, a carotenoid compound found in saffron, has demonstrated antioxidant and anti-inflammatory properties in various retinal diseases, but its efficacy in CSCR remains understudied.</div></div><div><h3>Methods</h3><div>In this randomized controlled trial, 40 patients with CSCR were assigned to receive either crocin (n=20) or placebo (n=20) over an eight-weeks period. Visual acuity, anatomical outcomes measured by optical coherence tomography (OCT), and adverse events were assessed at baseline and at the end of the intervention period.</div></div><div><h3>Results</h3><div>There were no significant differences observed in age, weight, body mass index, or gender distribution between the two groups (p > 0.05 for all comparisons). The changes in mean ETDRS letter score were significantly more in crocin group compared to the placebo group (4.27±3.63 vs 0.57±7.23, respectively, p=0.024). In the crocin group, 20 %, 40 % and 80 % of patients showed an improvement of 10,5 and 1 ETDRS letters, compared to only 7 %, 21 % and 29 % in the placebo group (p=0.316, p=0.280, p=0.005, respectively). While the crocin group exhibited greater mean reductions in sub-retinal fluid height, central macular thickness, and choroidal thickness compared to the placebo group, these differences did not reach statistical significance (p > 0.05 for all comparisons). No adverse events associated with the trial intervention were reported by any patient in either the crocin or placebo group.</div></div><div><h3>Conclusion</h3><div>The findings of this pilot study suggest that crocin supplementation may lead to improvements in visual acuity in patients with CSCR. Differences in anatomical outcomes between crocin and placebo groups did not reach statistical significance in this pilot study.</div></div>","PeriodicalId":20049,"journal":{"name":"PharmaNutrition","volume":"30 ","pages":"Article 100422"},"PeriodicalIF":2.4,"publicationDate":"2024-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142706094","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Dietitians’ knowledge and practice regarding inflammaging and related interventions: A pilot survey 营养师对炎症及相关干预措施的了解和实践：试点调查

IF 2.4 Q3 NUTRITION & DIETETICS

PharmaNutrition

Pub Date : 2024-11-08 DOI: 10.1016/j.phanu.2024.100420

Cato Wiegers, Sofia el Sarraf, Olaf F.A. Larsen

Background

The global population is aging rapidly, which is associated with an increase in chronic diseases. One of the possible underlying causes of these chronic diseases is inflammaging, characterised by the general low-grade inflammation that occurs in the body as we age. However, it is unclear to what extent this concept is already being considered as a base for prevention or therapy.

Methods

In this study, the willingness of practicing dietitians in the Netherlands to apply interventions targeting inflammaging was evaluated. Beforehand, a literature study was executed to identify possible parameters for intervention, covering most nutritional, biological, and medical aspects related to inflammaging. Based on the findings of the literature study, dietitians were asked about their awareness of the concept, the willingness to adopt more knowledge, and practical approaches regarding their clients.

Results

It was found that of the 56 surveyed dietitians, approximately two-third were already aware of the concept, and among this group, another two-third indicated that inflammaging plays a role in their provision of dietary advice. Generally, the information provided by the dietitians was in line with what was identified in literature.

Conclusions

As a first pilot, it appears that dietitians recognise the impact of nutrition and lifestyle factors on the progression of inflammaging. The willingness to adopt evidence-based practices signifies the importance of continued education and professional development in this area. Eventually, focusing on inflammaging in policy making could be a supporting factor for healthcare systems in the shift from curative to preventive care.

背景全球人口正在迅速老龄化，这与慢性疾病的增加有关。这些慢性疾病的潜在原因之一是炎症老化，其特点是随着年龄的增长，人体内会出现普遍的低度炎症。然而，目前还不清楚这一概念在多大程度上已被视为预防或治疗的基础。方法在这项研究中，我们评估了荷兰执业营养师采用针对炎症的干预措施的意愿。在此之前，我们进行了一项文献研究，以确定可能的干预参数，涵盖与炎症相关的大多数营养、生物和医学方面。结果发现，在接受调查的 56 名营养师中，约有三分之二已经了解这一概念，其中又有三分之二表示炎症在他们提供的饮食建议中发挥了作用。总体而言，营养师提供的信息与文献中指出的一致。结论作为首个试点，营养师似乎认识到营养和生活方式因素对炎症进展的影响。采用循证实践的意愿表明了在这一领域继续教育和专业发展的重要性。最终，在政策制定过程中关注炎症，可以成为医疗保健系统从治疗向预防转变的支持因素。

{"title":"Dietitians’ knowledge and practice regarding inflammaging and related interventions: A pilot survey","authors":"Cato Wiegers, Sofia el Sarraf, Olaf F.A. Larsen","doi":"10.1016/j.phanu.2024.100420","DOIUrl":"10.1016/j.phanu.2024.100420","url":null,"abstract":"<div><h3>Background</h3><div>The global population is aging rapidly, which is associated with an increase in chronic diseases. One of the possible underlying causes of these chronic diseases is inflammaging, characterised by the general low-grade inflammation that occurs in the body as we age. However, it is unclear to what extent this concept is already being considered as a base for prevention or therapy.</div></div><div><h3>Methods</h3><div>In this study, the willingness of practicing dietitians in the Netherlands to apply interventions targeting inflammaging was evaluated. Beforehand, a literature study was executed to identify possible parameters for intervention, covering most nutritional, biological, and medical aspects related to inflammaging. Based on the findings of the literature study, dietitians were asked about their awareness of the concept, the willingness to adopt more knowledge, and practical approaches regarding their clients.</div></div><div><h3>Results</h3><div>It was found that of the 56 surveyed dietitians, approximately two-third were already aware of the concept, and among this group, another two-third indicated that inflammaging plays a role in their provision of dietary advice. Generally, the information provided by the dietitians was in line with what was identified in literature.</div></div><div><h3>Conclusions</h3><div>As a first pilot, it appears that dietitians recognise the impact of nutrition and lifestyle factors on the progression of inflammaging. The willingness to adopt evidence-based practices signifies the importance of continued education and professional development in this area. Eventually, focusing on inflammaging in policy making could be a supporting factor for healthcare systems in the shift from curative to preventive care.</div></div>","PeriodicalId":20049,"journal":{"name":"PharmaNutrition","volume":"30 ","pages":"Article 100420"},"PeriodicalIF":2.4,"publicationDate":"2024-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142656416","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Exploring the molecular mechanisms and therapeutic benefits of L-theanine in counteracting inflammation 探索左旋茶氨酸对抗炎症的分子机制和治疗功效

IF 2.4 Q3 NUTRITION & DIETETICS

PharmaNutrition

Pub Date : 2024-11-03 DOI: 10.1016/j.phanu.2024.100419

Satarupa Deb , Anupom Borah

Chronic inflammation, a persistent condition that can significantly impact the body, is linked to the development and progression of numerous chronic degenerative diseases. Understanding its complex role is essential for discovering innovative therapeutic approaches, particularly those derived from natural sources. These strategies aim to reduce chronic inflammation and mitigate its associated diseases. Historically, natural products have been used for their therapeutic properties, including anti-inflammatory effects. They often offer advantages such as abundant availability, cost-effectiveness, and fewer side effects compared to synthetic drugs. L-theanine, an amino acid primarily found in tea leaves, has garnered significant attention for its potential health benefits, especially its anti-inflammatory properties. Research suggests that L-theanine may decrease levels of inflammatory markers in the body and modulate the immune system, preventing excessive inflammatory responses. While the growing evidence supports L-theanine's ability to attenuate harmful inflammation, the exact molecular mechanisms underlying its action remain largely unknown. This review seeks to elucidate these mechanisms, providing a comprehensive understanding of its role in modulating inflammation and its potential as a natural therapeutic agent.

慢性炎症是一种会对人体产生重大影响的持续性疾病，与多种慢性退行性疾病的发生和发展有关。了解慢性炎症的复杂作用对于发现创新的治疗方法至关重要，特别是那些从天然资源中提取的方法。这些策略旨在减少慢性炎症，减轻与之相关的疾病。从历史上看，天然产品因其治疗特性（包括抗炎作用）而被广泛使用。与合成药物相比，它们通常具有供应充足、成本效益高、副作用少等优势。L -茶氨酸是一种主要存在于茶叶中的氨基酸，因其潜在的健康益处，尤其是抗炎特性而备受关注。研究表明，L-茶氨酸可以降低体内炎症标志物的水平，调节免疫系统，防止过度的炎症反应。虽然越来越多的证据支持左旋茶氨酸能够减轻有害炎症，但其作用的确切分子机制在很大程度上仍不为人所知。本综述旨在阐明这些机制，全面了解它在调节炎症方面的作用及其作为天然治疗剂的潜力。

{"title":"Exploring the molecular mechanisms and therapeutic benefits of L-theanine in counteracting inflammation","authors":"Satarupa Deb , Anupom Borah","doi":"10.1016/j.phanu.2024.100419","DOIUrl":"10.1016/j.phanu.2024.100419","url":null,"abstract":"<div><div>Chronic inflammation, a persistent condition that can significantly impact the body, is linked to the development and progression of numerous chronic degenerative diseases. Understanding its complex role is essential for discovering innovative therapeutic approaches, particularly those derived from natural sources. These strategies aim to reduce chronic inflammation and mitigate its associated diseases. Historically, natural products have been used for their therapeutic properties, including anti-inflammatory effects. They often offer advantages such as abundant availability, cost-effectiveness, and fewer side effects compared to synthetic drugs. L-theanine, an amino acid primarily found in tea leaves, has garnered significant attention for its potential health benefits, especially its anti-inflammatory properties. Research suggests that L-theanine may decrease levels of inflammatory markers in the body and modulate the immune system, preventing excessive inflammatory responses. While the growing evidence supports L-theanine's ability to attenuate harmful inflammation, the exact molecular mechanisms underlying its action remain largely unknown. This review seeks to elucidate these mechanisms, providing a comprehensive understanding of its role in modulating inflammation and its potential as a natural therapeutic agent.</div></div>","PeriodicalId":20049,"journal":{"name":"PharmaNutrition","volume":"30 ","pages":"Article 100419"},"PeriodicalIF":2.4,"publicationDate":"2024-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142656414","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Enhanced absorption of omega-3 fatty acids from a novel krill oil-derived phospholipid formulation compared to fish oil ethyl esters: A randomized, two-way crossover pharmacokinetic study 与鱼油乙酯相比，新型磷虾油磷脂配方能促进ω-3脂肪酸的吸收：随机双向交叉药代动力学研究

IF 2.4 Q3 NUTRITION & DIETETICS

PharmaNutrition

Pub Date : 2024-11-02 DOI: 10.1016/j.phanu.2024.100417

Christiane Schoen , Line Johnsen , Antje Micka , Manfred Wilhelm , Yunpeng Ding

Background

Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) offer many health benefits, yet the absorption from standard ethyl ester (EE) formulation requires concurrent intake of a fatty meal. This study aimed to evaluate the absorption of EPA and DHA from a novel omega-3 formulation, Phospholipids + EPA/DHA (PL+), which combines high phospholipdi krill oil (KO) and EE, in comparison to a standard EE product under a low-fat dietary condition in healthy adults.

Methods

In this randomized, cross-over, single-dose study, the pharmacokinetic profiles of EPA and DHA from PL+ and EE product was assessed. Each products contained approximately 1200 mg EPA+DHA. Participants consumed a single dose of the capsules under a low-fat diet regimen, with plasma samples collected at baseline and over a 72-hour period after dosing. Following a 14-day washout period, participants crossed over to the alternate treatment. Plasma concentrations of EPA, DHA, and combined EPA+DHA were analyzed.

Results

Twelve participants (six women and six men) were included, completed all study visits and were included in the analyses. The participants' mean age was 34.3 years (SD = 12.4), and the mean BMI was 22.6 kg/m² (SD = 3.2). The baseline-corrected incremental area under the curve (iAUC_0–12h) for combined EPA+DHA was significantly higher for PL+ (255.5 [SD = 81.4] μg/mL*h) compared to EE (34.2 [SD = 33.4] μg/mL*h; P < 0.001). The treatment ratio of iAUC_0–12h for PL+ relative to EE was 10.5 (95 % CI: 6.1 – 18.1; P < 0.001). Similar patterns were observed for iAUC_0–24h and iAUC_0–72h for combined EPA+DHA, as well as for EPA and DHA individually. Sensitivity analyses by adjusting the minimal difference on dose between products yielded consistent findings.

Conclusions

The results indicate that PL+ technology significantly enhances the absorption of EPA and DHA compared to standard EE alone in a low-fat dietary condition. These outcomes suggest that the absorption of EE formulations can be significantly improved through combination with high phospholipid krill oil, as evidenced by the performance of the PL+ formulation.

背景二十碳五烯酸（EPA）和二十二碳六烯酸（DHA）具有许多健康益处，但要从标准乙酯（EE）配方中吸收这两种物质，需要同时摄入脂肪餐。本研究旨在评估健康成年人在低脂饮食条件下，与标准 EE 产品相比，对新型欧米伽-3 配方磷脂 + EPA/DHA (PL+) 中 EPA 和 DHA 的吸收情况，该配方结合了高磷脂磷虾油 (KO) 和 EE。每种产品都含有约 1200 毫克 EPA+DHA。参与者在低脂饮食方案下服用单剂量胶囊，并在基线和服药后 72 小时内采集血浆样本。经过 14 天的冲洗期后，参与者换用另一种疗法。结果有 12 名参与者（6 名女性和 6 名男性）完成了所有研究访问并被纳入分析。参与者的平均年龄为 34.3 岁（SD = 12.4），平均体重指数为 22.6 kg/m²（SD = 3.2）。与 EE（34.2 [SD = 33.4] μg/mL*h；P <0.001）相比，PL+（255.5 [SD = 81.4] μg/mL*h）的 EPA+DHA 组合基线校正增量曲线下面积（iAUC0-12h）明显更高。相对于 EE，PL+ 的 iAUC0-12h 治疗比为 10.5（95 % CI：6.1 - 18.1；P <；0.001）。对于 EPA+DHA 组合以及单独的 EPA 和 DHA，iAUC0-24h 和 iAUC0-72h 也观察到类似的模式。结果表明，在低脂饮食条件下，与单独使用标准 EE 相比，PL+ 技术能显著提高 EPA 和 DHA 的吸收。这些结果表明，通过与高磷脂磷虾油的结合，EE 配方的吸收可以得到明显改善，PL+ 配方的表现就是证明。

{"title":"Enhanced absorption of omega-3 fatty acids from a novel krill oil-derived phospholipid formulation compared to fish oil ethyl esters: A randomized, two-way crossover pharmacokinetic study","authors":"Christiane Schoen , Line Johnsen , Antje Micka , Manfred Wilhelm , Yunpeng Ding","doi":"10.1016/j.phanu.2024.100417","DOIUrl":"10.1016/j.phanu.2024.100417","url":null,"abstract":"<div><h3>Background</h3><div>Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) offer many health benefits, yet the absorption from standard ethyl ester (EE) formulation requires concurrent intake of a fatty meal. This study aimed to evaluate the absorption of EPA and DHA from a novel omega-3 formulation, Phospholipids + EPA/DHA (PL+), which combines high phospholipdi krill oil (KO) and EE, in comparison to a standard EE product under a low-fat dietary condition in healthy adults.</div></div><div><h3>Methods</h3><div>In this randomized, cross-over, single-dose study, the pharmacokinetic profiles of EPA and DHA from PL+ and EE product was assessed. Each products contained approximately 1200 mg EPA+DHA. Participants consumed a single dose of the capsules under a low-fat diet regimen, with plasma samples collected at baseline and over a 72-hour period after dosing. Following a 14-day washout period, participants crossed over to the alternate treatment. Plasma concentrations of EPA, DHA, and combined EPA+DHA were analyzed.</div></div><div><h3>Results</h3><div>Twelve participants (six women and six men) were included, completed all study visits and were included in the analyses. The participants' mean age was 34.3 years (SD = 12.4), and the mean BMI was 22.6 kg/m² (SD = 3.2). The baseline-corrected incremental area under the curve (iAUC<sub>0–12h</sub>) for combined EPA+DHA was significantly higher for PL+ (255.5 [SD = 81.4] μg/mL*h) compared to EE (34.2 [SD = 33.4] μg/mL*h; P < 0.001). The treatment ratio of iAUC<sub>0–12h</sub> for PL+ relative to EE was 10.5 (95 % CI: 6.1 – 18.1; P < 0.001). Similar patterns were observed for iAUC<sub>0–24h</sub> and iAUC<sub>0–72h</sub> for combined EPA+DHA, as well as for EPA and DHA individually. Sensitivity analyses by adjusting the minimal difference on dose between products yielded consistent findings.</div></div><div><h3>Conclusions</h3><div>The results indicate that PL+ technology significantly enhances the absorption of EPA and DHA compared to standard EE alone in a low-fat dietary condition. These outcomes suggest that the absorption of EE formulations can be significantly improved through combination with high phospholipid krill oil, as evidenced by the performance of the PL+ formulation.</div></div>","PeriodicalId":20049,"journal":{"name":"PharmaNutrition","volume":"30 ","pages":"Article 100417"},"PeriodicalIF":2.4,"publicationDate":"2024-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142656415","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Milk fat globule membrane: Production, digestion, and health benefits evaluated through in vitro models 牛奶脂肪球膜：通过体外模型评估生产、消化和健康益处

IF 2.4 Q3 NUTRITION & DIETETICS

PharmaNutrition

Pub Date : 2024-10-31 DOI: 10.1016/j.phanu.2024.100418

Victoria Martínez-Sánchez , Javier Fontecha , Antonio Pérez-Gálvez

Background

Milk is a biologically complex fluid with a primary function as a bioactive compound and energy source for the offspring in the early stages of life. This role is largely due to its high lipid content, encapsulated in globules known as milk fat globules (MFG). Extensive research has led to the conclusion that MFGs are not only energy carriers, as they are surrounded by a milk fat globule membrane (MFGM) which is characterized by its complex architecture and bioactive components such as polar lipids and glycoproteins.

Methods

This literature review was performed by an extensive search of Pubmed, Scopus or Google Scholar database for studies using keywords such as “lactation”, “milk production”, “MFG”, “MFGM”, “polar lipids”, “in vitro”, “milk lipids”, “health benefits”, “human health”, “digestion”, “bioaccessibility”, “bioavailability”.

Results

Brain and intestinal development, modulation of the microbiota or the correct immunological response to infections are some of the benefits that MFGM has in infants. In addition, its therapeutic potential is extended to the adult population through the attenuation of lipid metabolism disorders or the prevention of neurodegenerative diseases. Consequently, the trend in the food industry is to incorporate this MFGM concentrate as a bioactive ingredient in functional foods.

Conclusion

This review provides an overview of the natural and industrial production of MFGM and their relationship to the health benefits identified in in vitro studies. Furthermore, this review highlights the importance of further research to understand the assimilation of MFGM lipids to optimize its incorporation into the human diet.

背景牛奶是一种具有生物活性的复杂液体，其主要功能是作为生物活性化合物和生命早期阶段后代的能量来源。这种作用主要是由于牛奶中含有大量脂质，这些脂质包裹在被称为乳脂球（MFG）的球状物中。大量研究得出的结论是，乳脂球不仅是能量载体，还被乳脂球膜（MFGM）所包围，而乳脂球膜的特点是结构复杂，并含有极性脂质和糖蛋白等生物活性成分。方法通过在 Pubmed、Scopus 或 Google Scholar 数据库中使用 "泌乳"、"牛奶生产"、"MFG"、"MFGM"、"极性脂质"、"体外"、"牛奶脂质"、"健康益处"、"人类健康"、"消化"、"生物可及性"、"生物利用度 "等关键词广泛搜索相关研究，进行本文献综述。结果婴儿脑部和肠道发育、微生物群调节或对感染的正确免疫反应是牛奶中脂质对婴儿的一些益处。此外，通过减轻脂质代谢紊乱或预防神经退行性疾病，其治疗潜力也扩展到了成年人群。因此，食品行业的趋势是将这种 MFGM 浓缩物作为一种生物活性成分纳入功能性食品中。结论本综述概述了天然和工业生产的 MFGM 及其与体外研究发现的健康益处之间的关系。此外，本综述还强调了进一步研究了解 MFGM 脂类同化的重要性，以优化其在人类饮食中的应用。

{"title":"Milk fat globule membrane: Production, digestion, and health benefits evaluated through in vitro models","authors":"Victoria Martínez-Sánchez , Javier Fontecha , Antonio Pérez-Gálvez","doi":"10.1016/j.phanu.2024.100418","DOIUrl":"10.1016/j.phanu.2024.100418","url":null,"abstract":"<div><h3>Background</h3><div>Milk is a biologically complex fluid with a primary function as a bioactive compound and energy source for the offspring in the early stages of life. This role is largely due to its high lipid content, encapsulated in globules known as milk fat globules (MFG). Extensive research has led to the conclusion that MFGs are not only energy carriers, as they are surrounded by a milk fat globule membrane (MFGM) which is characterized by its complex architecture and bioactive components such as polar lipids and glycoproteins.</div></div><div><h3>Methods</h3><div>This literature review was performed by an extensive search of Pubmed, Scopus or Google Scholar database for studies using keywords such as “lactation”, “milk production”, “MFG”, “MFGM”, “polar lipids”, “in vitro”, “milk lipids”, “health benefits”, “human health”, “digestion”, “bioaccessibility”, “bioavailability”.</div></div><div><h3>Results</h3><div>Brain and intestinal development, modulation of the microbiota or the correct immunological response to infections are some of the benefits that MFGM has in infants. In addition, its therapeutic potential is extended to the adult population through the attenuation of lipid metabolism disorders or the prevention of neurodegenerative diseases. Consequently, the trend in the food industry is to incorporate this MFGM concentrate as a bioactive ingredient in functional foods.</div></div><div><h3>Conclusion</h3><div>This review provides an overview of the natural and industrial production of MFGM and their relationship to the health benefits identified in in vitro studies. Furthermore, this review highlights the importance of further research to understand the assimilation of MFGM lipids to optimize its incorporation into the human diet.</div></div>","PeriodicalId":20049,"journal":{"name":"PharmaNutrition","volume":"30 ","pages":"Article 100418"},"PeriodicalIF":2.4,"publicationDate":"2024-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142586171","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Advancements in psoriasis management: Integrating nutrient supplement with gut-brain-skin connection 牛皮癣治疗的进展：将营养补充剂与肠道-大脑-皮肤的联系结合起来

IF 2.4 Q3 NUTRITION & DIETETICS

PharmaNutrition

Pub Date : 2024-10-24 DOI: 10.1016/j.phanu.2024.100416

Smriti Mishra , Shikha Saxena , Rajendra Awasthi

Background

Psoriasis is a chronic inflammatory skin disease that affects a large population globally and poses a significant challenge in clinical care due to its multifaceted characteristics. Recent studies show the relationship between the gut, brain, and skin, unveiling the potential for novel therapeutic approaches.

Methods

This review includes papers published from 1991 to 2024 exploring various advancements in psoriasis management. We also explored various techniques to encapsulate natural bioactive molecules with anti-psoriatic activity. The published articles were searched using various databases, including Scopus, Web of Science, Clinical Trials, and Google Scholar.

Results

The gut microbiome contains numerous microorganisms that influence immune regulation and inflammation. The pathogenesis of psoriasis has implicated an imbalance in gut microbes, known as gut dysbiosis. Probiotics, prebiotics, and other dietary interventions can help restore microbial balance and improve psoriasis symptoms. Furthermore, the gut microbiota can modulate neurotransmitters and neuropeptides, impacting communication between the gut, brain, and skin. Stress, a well-established trigger for psoriasis exacerbations, disrupts the gut-brain-skin axis. Nutrient supplements like omega-3 fatty acids, polyphenols, probiotic supplements, herbal supplements, etc. can reduce inflammation and enhance skin health. Deficiency in nutrients like vitamin D may contribute to psoriasis development. Targeting inflammatory pathways, balancing gut microbiomes, and addressing nutritional deficiencies can improve psoriasis treatment outcomes.

Conclusion

Natural bioactives have demonstrated antipsoriatic efficacy in several preclinical and clinical studies done in more recent years. Large-scale clinical trials using encapsulated natural bioactives are still needed to demonstrate their antipsoriatic activity and ability to regulate the gut-brain-skin axis.

背景银屑病是一种慢性炎症性皮肤病，影响着全球众多人群，由于其多方面的特点，给临床治疗带来了巨大挑战。最近的研究显示了肠道、大脑和皮肤之间的关系，揭示了新型治疗方法的潜力。方法本综述收录了 1991 年至 2024 年发表的论文，探讨了银屑病治疗的各种进展。我们还探讨了封装具有抗银屑病活性的天然生物活性分子的各种技术。我们使用 Scopus、Web of Science、Clinical Trials 和 Google Scholar 等多个数据库对已发表的文章进行了检索。银屑病的发病机制与肠道微生物失衡有关，即肠道菌群失调。益生菌、益生元和其他饮食干预措施有助于恢复微生物平衡，改善银屑病症状。此外，肠道微生物群还能调节神经递质和神经肽，影响肠道、大脑和皮肤之间的交流。压力是牛皮癣加重的公认诱因，会破坏肠道-大脑-皮肤轴。欧米伽-3 脂肪酸、多酚、益生菌补充剂、草药补充剂等营养补充剂可以减轻炎症，增强皮肤健康。缺乏维生素 D 等营养素可能会导致牛皮癣的发生。针对炎症途径、平衡肠道微生物群和解决营养缺乏问题可以改善银屑病的治疗效果。要证明天然生物活性物质的抗银屑病活性和调节肠道-大脑-皮肤轴的能力，还需要使用封装的天然生物活性物质进行大规模临床试验。

{"title":"Advancements in psoriasis management: Integrating nutrient supplement with gut-brain-skin connection","authors":"Smriti Mishra , Shikha Saxena , Rajendra Awasthi","doi":"10.1016/j.phanu.2024.100416","DOIUrl":"10.1016/j.phanu.2024.100416","url":null,"abstract":"<div><h3>Background</h3><div>Psoriasis is a chronic inflammatory skin disease that affects a large population globally and poses a significant challenge in clinical care due to its multifaceted characteristics. Recent studies show the relationship between the gut, brain, and skin, unveiling the potential for novel therapeutic approaches.</div></div><div><h3>Methods</h3><div>This review includes papers published from 1991 to 2024 exploring various advancements in psoriasis management. We also explored various techniques to encapsulate natural bioactive molecules with anti-psoriatic activity. The published articles were searched using various databases, including Scopus, Web of Science, Clinical Trials, and Google Scholar.</div></div><div><h3>Results</h3><div>The gut microbiome contains numerous microorganisms that influence immune regulation and inflammation. The pathogenesis of psoriasis has implicated an imbalance in gut microbes, known as gut dysbiosis. Probiotics, prebiotics, and other dietary interventions can help restore microbial balance and improve psoriasis symptoms. Furthermore, the gut microbiota can modulate neurotransmitters and neuropeptides, impacting communication between the gut, brain, and skin. Stress, a well-established trigger for psoriasis exacerbations, disrupts the gut-brain-skin axis. Nutrient supplements like omega-3 fatty acids, polyphenols, probiotic supplements, herbal supplements, <em>etc</em>. can reduce inflammation and enhance skin health. Deficiency in nutrients like vitamin D may contribute to psoriasis development. Targeting inflammatory pathways, balancing gut microbiomes, and addressing nutritional deficiencies can improve psoriasis treatment outcomes.</div></div><div><h3>Conclusion</h3><div>Natural bioactives have demonstrated antipsoriatic efficacy in several preclinical and clinical studies done in more recent years. Large-scale clinical trials using encapsulated natural bioactives are still needed to demonstrate their antipsoriatic activity and ability to regulate the gut-brain-skin axis.</div></div>","PeriodicalId":20049,"journal":{"name":"PharmaNutrition","volume":"30 ","pages":"Article 100416"},"PeriodicalIF":2.4,"publicationDate":"2024-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142553427","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0